高病毒载量慢性乙型肝炎的危害

doi:10.3969/j.issn.1000-8535.2024.07.002

摘要/Abstract

摘要： 慢性乙型肝炎（CHB）是我国常见的传染病,随着乙型肝炎病毒（HBV）在体内持续活跃复制可进展为肝硬化甚至肝癌,严重威胁患者健康与生命,而高病毒载量CHB患者不仅进展为肝硬化、肝癌的风险和发生母婴垂直传播的风险增加,还存在抗病毒治疗病毒学应答率偏低等特点,目前对高病毒载量CHB患者的管理已引起国内外学者的关注,但尚缺乏系统的研究与阐述。本文将针对上述问题结合国内外相关文献进行综述,期望今后本领域学者对高病毒载量CHB这类特殊患者能有更深入的研究。

关键词: 慢性乙型肝炎, 高病毒载量

Abstract: Chronic hepatitis B（CHB）is a common infectious disease in China．With the continuous active replication of hepatitis B virus（HBV）in the body,cirrhosis and even liver cancer can progress,seriously threatening the health and life of patients．However,CHB patients with high viral load not only have an increased risk of cirrhosis and liver cancer,mother-to-child vertical transmission,but also with a lower rate of virological response to antiviral therapy．At present,the management of CHB patients with high viral load has attracted the attention of scholars at home and abroad,but there is still a lack of systematic research and elaboration．This paper will focus on the above problems combined with relevant domestic and foreign literature review,hoping that scholars in this field can have more in-depth research on special patients with high viral load CHB in the future．

Key words: chronic hepatitis B, high viral load

邓玕, 简希尧. 高病毒载量慢性乙型肝炎的危害[J]. 广州医药, 2024, 55(7): 705-711.

DENG Gan, JIAN Xiyao. Overview of the harms of chronic hepatitis B with high viral load[J]. Guangzhou Medical Journal, 2024, 55(7): 705-711.

参考文献

[1] 曾红梅,蔡建强.中国肝癌诊治现状再思考[J].肝癌电子杂志,2021,8(2):23-25.
[2] YANG Y,GAO J,TAN Y T,et al.Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk[J]. J Gastroenterol Hepatol,2018,33(5):1131-1137.
[3] 任丹丹,刘娜,周路路,等.HBV相关肝细胞癌的危险因素[J].临床肝胆病杂志,2020,36(7):1634-1638.
[4] 王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年版)[J].实用肝脏病杂志,2016,19(3):389-400.
[5] 郭丽玲. 分析恩替卡韦与替诺福韦二吡呋酯治疗高病毒载量慢性乙型肝炎患者的效果[J].北方药学,2023,20(5):47-49.
[6] 蔡晓娟,朱晓红,薛红.替比夫定和恩替卡韦在高病毒载量乙肝患者治疗中的远期疗效比较[J].现代消化及介入诊疗,2020,25(9):1194-1196.
[7] 陈潇潇. 恩替卡韦和替比夫定治疗高病毒载量慢性乙型肝炎患者的远期疗效分析[J].当代医学,2020,26(30):184-186.
[8] 张蕾. 扶正化瘀胶囊联合恩替卡韦和熊去氧胆酸对HBeAg阳性高病毒载量乙肝肝硬化患者抗病毒疗效及肝功能、肝纤维化和炎症反应的影响[J].药物评价研究,2019,42(4):739-742.
[9] HUANG M,ZHONG J,LU C,et al.Genotypic resistance remains a concern in chronic hepatitis B patients with high viral load after lamivudine and adefovir combination therapy[J].Pharmgenomics Pers Med,2019(12):297-303.
[10] 王辉. 恩替卡韦与替诺福韦酯治疗高病毒载量慢性乙型肝炎患者的临床效果分析[J].系统医学,2022,7(16):100-103,132.
[11] 周珲堃,江建宁,苏明华,等.恩替卡韦与替诺福韦酯治疗高病毒载量慢性乙型肝炎患者的效果分析[J].临床肝胆病杂志,2022,38(3):532-536.
[12] 王磊,赵鹏,石盾.不同剂量恩替卡韦治疗高病毒载量e抗原阳性乙型肝炎的效果及安全性分析[J].解放军医药杂志,2018,30(6):72-74,95.
[13] European Association for the Study of the Liver.Electronic address:Easloffice@easloffice.eu;European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67(2):370-398.
[14] LOK A S,TRINH H,CAROSI G,et al.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B[J]. Gastroenterology,2012,143(3):619-628.
[15] GORDON S C,KRASTEV Z,HORBAN A,et al.Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load[J].Hepatology,2013, 58(2):505-513.
[16] FRAGER S Z,SCHWARTZ J M.Hepatocellular carcinoma:epidemiology,screening,and assessment of hepatic reserve[J]. Curr Oncol,2020,27(Suppl 3):S138-S143.
[17] CHEN C J,YANG H I,SU J,et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006,295(1):65-73.
[18] ILOEJE U H,YANG H I,SU J,et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J]. Gastroenterology, 2006,130(3):678-686.
[19] CHOI W M,KIM G A,CHOI J,et al.Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B[J].Gut,2024,73(4):649-658.
[20] 郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析[J].陕西医学杂志,2019,48(7):850-852.
[21] 孟金霞,卢喜玲,别文倩,等.乙肝肝硬化并发原发性肝癌的相关危险因素分析[J].实用癌症杂志,2022,37(5):777-779.
[22] 谢露,刘光伟,郭会军.HBV DNA载量水平与乙型肝炎相关肝癌指标的相关性分析及其对预后的影响[J].中西医结合肝病杂志,2023,33(10):925-929.
[23] 王燕. 乙肝病毒载量对中晚期肝癌患者生存率的影响[J].世界最新医学信息文摘,2021,21(91):37-38.
[24] YANG Y,WEN F,LI J,et al.A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib[J].Liver Int, 2015,35(9):2147-2154.
[25] LI L,LI B,ZHANG M.HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion[J].Medicine(Baltimore),2019,98(27):e16308.
[26] YIN G,ZHANG N,BUHE A,et al.Risk factors of secondary infection/recurrence after ablation for liver cancers:A systemic review and meta-analysis[J].J Cancer Res Ther,2022,18(5):1352-1359.
[27] GIOSA D,LOMBARDO D,MUSOLINO C,et al.Mitochondrial DNA is a target of HBV integration[J].Commun Biol,2023,6(1):684.
[28] PODLAHA O,WU G,DOWNIE B,et al.Genomic modeling of hepatitis B virus integration frequency in the human genome[J].PLoS One,2019,14(7):e0220376.
[29] GUO M,ZHAO L,JIANG C,et al.Multiomics analyses reveal pathological mechanisms of HBV infection and integration in liver cancer[J].J Med Virol,2023,95(8):e28980.
[30] ÁLVAREZ E G,DEMEULEMEESTER J,OTERO P,et al.Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture[J].Nat Commun,2021,12(1):6910.
[31] JIANG Y,HAN Q,ZHAO H,et al.The mechanisms of HBV-induced hepatocellular carcinoma[J].J Hepatocell Carcinoma,2021(8):435-450.
[32] GLITSCHER M,HILDT E,BENDER D.Hepatitis B und C:Mechanismen der virusinduzierten leberpathogenese und tumorentstehung[Hepatitis B and C:mechanisms of virus-induced liver pathogenesis and tumorigenesis][J].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,2022,65(2):228-237.
[33] ODA C,KAMIMURA K,SHIBATA O,et al.HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma[J].Biochem Biophys Rep,2022(32):101352.
[34] QU S,JIN L,HUANG H,et al.A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis[J]. BMC Cancer,2021,21(1):686.
[35] SIVASUDHAN E,BLAKE N,LU Z,et al.Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma:A comprehensive review[J].Cells,2022,11(4):741.
[36] 吴勇,况钦,周梦瑶,等.SNHG12在乙肝病毒X蛋白诱导肝癌发生中的作用研究[J].广州医药,2023,54(1):16-24,43.
[37] WANG Y F,ZHAO M,ZHAO L,et al.HBx-induced HSPA8 stimulates HBV replication and suppresses ferroptosis to support liver cancer progression[J]. Cancer Res,2023,83(7):1048-1061.
[38] 刘春云,常丽仙,李俊义,等.HBV感染免疫耐受期肝组织炎症和纤维化的影响因素分析[J].临床肝胆病杂志, 2022,38(9):2005-2009.
[39] HONG Y M,YOON K T.Definition and management of the immune tolerance phase in chronic hepatitis B[J].Korean J Gastroenterol,2022,79(4):156-160.
[40] YOO J J,PARK S Y,MOON J E,et al.Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase[J].Clin Mol Hepatol,2023,29(2):482-495.
[41] 黄燕,杜冰莹,谢青.HBeAg阳性且高病毒载量ALT正常慢性HBV感染患者应尽早抗病毒治疗[J].中华肝脏病杂志,2023,31(3):233-237.
[42] KIM G A,LIM Y S,HAN S,et al.High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J].Gut,2018,67(5):945-952.
[43] FUNG S,GORDON S C,KROSTEV Z,et al.Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load(≥ 9 log10 copies/ml)[J].Liver Int,2015,35(2):422-428.
[44] YAN L B,CHEN E Q,BAI L,et al.Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load[J].Clin Res Hepatol Gastroenterol,2015,39(3):366-372.
[45] 王璐,代晶芳,张国梅.HBV高病毒载量孕妇与新生儿宫内感染的相关性分析[J].中华医院感染学杂志,2018,28(4):586-589,597.
[46] BOUCHERON P,LU Y,YOSHIDA K,et al.Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates:A systematic review and meta-analysis[J].Lancet Infect Dis,2021,21(1):85-96.
[47] VERONESE P,DODI I,ESPOSITO S,et al.Prevention of vertical transmission of hepatitis B virus infection[J].World J Gastroenterol,2021,27(26):4182-4193.
[48] 张宝芳,程明亮,张权,等.贵州地区HBeAg阳性乙型肝炎病毒高载量孕妇母婴阻断的临床研究[J].中华肝脏病杂志,2018, 26(12):945-950.
[49] 赵红萍,周鸿良,王悦.孕早期胎盘HBV感染的危险因素分析[J].中国预防医学杂志,2019,20(9):858-861.
[50] WU C H,HUANG W C,CHEN C H,et al.Outcomes of hepatitis B immunoglobulin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers[J].Biomed J,2022,45(5):798-805.
[51] PENG T T,CAI Q E,YANG M,et al.Epidemiological trends and virological traits of hepatitis B virus infection in pregnant women and neonates[J].Arch Virol,2019,164(5):1335-1341.
[52] 王静,闫涛涛,冯亚丽,等.母亲HBV DNA 载量对宫内传播及胎儿窘迫的影响[J].中华肝脏病杂志,2022, 30(8):873-878.
[53] 彭湾,曹红.高病毒载量慢性乙型肝炎抗病毒治疗研究进展[J].新医学,2022,53(8):551-554.